GlassScriptPhysician profile
John Angiel
NPI 1386388445
$455.97
in general payments reported to CMS, 2019-2025
13 companies · $456 in 2025
The $456 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.70 | 2025 | Caplyta |
| Pfizer INC. | $56.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $46.72 | 2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $45.29 | 2025 | Rexulti |
| Exact Sciences Corporation | $45.28 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $40.95 | 2025 | |
| Novo Nordisk INC | $34.23 | 2025 | Rybelsus, Ozempic |
| Radius Health, INC. | $24.25 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $23.04 | 2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $19.63 | 2025 | M-M-R II, Capvaxive, Enflonsia |
| Abbvie INC. | $19.10 | 2025 | |
| Lilly USA, LLC | $16.13 | 2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $13.67 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Angiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.